4.6 Article

Frequency of Testing to Detect Visual Field Progression Derived Using a Longitudinal Cohort of Glaucoma Patients

Journal

OPHTHALMOLOGY
Volume 124, Issue 6, Pages 786-792

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ophtha.2017.01.027

Keywords

-

Categories

Funding

  1. National Eye Institute, National Institutes of Health, Bethesda, Maryland [EY021818, P30EY022589]
  2. Alcon, Fort Worth, TX
  3. Allergan, Irvine, CA
  4. Pfizer, New York, NY
  5. Merck, White House Station, NJ
  6. Santen
  7. National Health and Medical Research Council [1104985]
  8. Brazilian National Council for Scientific and Technological Development (CNPq) [233829/2014-8]
  9. Prevent Blindness, Inc., New York, New York
  10. Alcon Laboratories (Fort Worth, TX)
  11. Bausch & Lomb (Garden City, NY)
  12. Carl-Zeiss Meditec (Jena, Germany)
  13. Heidelberg Engineering (Heidelberg, Germany)
  14. Merck (White House Station, NJ)
  15. Allergan (Irvine, CA)
  16. Sensimed (Lausanne, Switzerland)
  17. Topcon (Livermore, CA)
  18. Reichert (Dewey, NY)

Ask authors/readers for more resources

Purpose: To determine the time required to detect statistically significant progression for different rates of visual field loss using standard automated perimetry (SAP) when considering different frequencies of testing using a follow-up scheme that resembles clinical practice. Design: Observational cohort study. Participants: One thousand seventy-two eyes of 665 patients with glaucoma followed up over an average of 4.3 +/- 0.9 years. Methods: Participants with 5 or more visual field tests over a 2- to 5-year period were included to derive the longitudinal measurement variability of SAP mean deviation (MD) using linear regressions. Estimates of variability then were used to reconstruct real-world visual field data by computer simulation to evaluate the time required to detect progression for various rates of visual field loss and different frequencies of testing. The evaluation was performed using a follow-up scheme that resembled clinical practice by requiring a set of 2 baseline tests and a confirmatory test to identify progression. Main Outcome Measures: Time (in years) required to detect progression. Results: The time required to detect a statistically significant negative MD slope decreased as the frequency of testing increased, albeit not proportionally. For example, 80% of eyes with an MD loss of - 2 dB/year would be detected after 3.3, 2.4, and 2.1 years when testing is performed once, twice, and thrice per year, respectively. For eyes with an MD loss of -0.5 dB/year, progression can be detected with 80% power after 7.3, 5.7, and 5.0 years, respectively. Conclusions: This study provides information on the time required to detect progression using MD trend analysis in glaucoma eyes when different testing frequencies are used. The smaller gains in the time to detect progression when testing is increased from twice to thrice per year suggests that obtaining 2 reliable tests at baseline followed by semiannual testing and confirmation of progression through repeat testing in the initial years of follow-up may provide a good compromise for detecting progression, while minimizing the burden on health care resources in clinical practice. (C) 2017 by the American Academy of Ophthalmology

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available